IDH1 and cholangiocarcinoma: Despite the geneticdiversity, a recurrent repertoire of driver genes and potentially targetable lesionsexists: indeed, several studies suggest that about 40% of patients harbor targetablealterations, indicating precision oncology has the potential to complement existingtherapies.6, , , –10 Recently, the first randomizedphase III study that investigated a precision oncology-based concept in agenetically selected CCA patient cohort was completed and reported positive data forthe IDH-inhibitor ivosidenib in IDH1 mutant patients.11